Protara Therapeutics (TARA) Common Equity (2013 - 2026)
Protara Therapeutics (TARA) posted quarterly Common Equity of $181.2 million for Q1 2026, up 14.34% year-over-year from $158.5 million in Q1 2025, and down 7.74% quarter-over-quarter from $196.4 million in Q4 2025.
Protara Therapeutics (TARA) Common Equity (2013 - 2026) Analysis & Trends
Protara Therapeutics (TARA) has reported Common Equity for 14 consecutive years, with $181.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 14.34% year-over-year to $181.2 million; the TTM figure through Mar 2026 stood at $181.2 million (up 14.34% YoY), while the FY2025 annual figure was $196.4 million, up 17.52% from the prior year.
- Common Equity eased to $181.2 million in Q1 2026 per TARA's latest filing, from $196.4 million in the prior quarter.
- Across five years, Common Equity topped out at $196.4 million in Q4 2025 and bottomed at $58.4 million in Q1 2024.
- Historically, Common Equity has averaged $122.1 million across 5 years, with a median of $132.3 million in 2025.
- Annual changes were most pronounced in 2023 — Common Equity sank 44.71% — and 2025, when it surged 171.35%.
- Protara Therapeutics' Common Equity stood at $102.1 million in 2022, then plunged by 33.07% to $68.3 million in 2023, then surged by 144.63% to $167.1 million in 2024, then gained by 17.52% to $196.4 million in 2025, then declined by 7.74% to $181.2 million in 2026.
- Business Quant data shows TARA's Common Equity at $181.2 million in Q1 2026, $196.4 million in Q4 2025, and $132.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Protara Therapeutics | 234.56 Mn | 234.56 Mn | - | 161.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 161.31 Mn |
| Mar 31, 2026 | 181.21 Mn |
| Dec 31, 2025 | 196.41 Mn |
| Sep 30, 2025 | 132.29 Mn |
| Jun 30, 2025 | 144.42 Mn |
| Mar 31, 2025 | 158.48 Mn |
| Dec 31, 2024 | 167.13 Mn |
| Sep 30, 2024 | 81.79 Mn |
| Jun 30, 2024 | 92.05 Mn |
| Mar 31, 2024 | 58.41 Mn |
| Dec 31, 2023 | 68.32 Mn |
| Sep 30, 2023 | 76.96 Mn |
| Jun 30, 2023 | 85.23 Mn |
| Mar 31, 2023 | 94.77 Mn |
| Dec 31, 2022 | 102.08 Mn |
| Sep 30, 2022 | 139.18 Mn |
| Jun 30, 2022 | 145.46 Mn |
| Mar 31, 2022 | 152.24 Mn |
| Dec 31, 2021 | 161.91 Mn |
| Sep 30, 2021 | 170.41 Mn |